RxDoctor Payments Data

Claudia Padilla, MD

Neurology · Dallas, TXNPI 1689816845

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,985 of the $19,417 with a category attached, or 66.9%. Eisai Inc. accounts for 75.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $8,851 and has fallen 94.4% since, to $495 in 2025.

$19,418in general payments, 2019–2025

Across 96 payments — averaging $202.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$15K
  • Life Molecular Imaging Ltd$4K
  • Lilly USA, LLC$624
  • GE HealthCare$103
  • Otsuka America Pharmaceutical, Inc.$90
  • Biogen$84
  • plus $233 from 6 others
$804,234in research payments, 2019–2025

Across 26 payments — averaging $30,932 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$804K

What the payments were for

  • Consulting fees$12,98567%
  • Speaking & faculty fees$3,60019%
  • Travel & lodging$6914%
  • Food & beverage$2,09811%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,418 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$108,703
Medicare patients
503
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NamzaricMemantine Hcl/Donepezil Hcl28$46,153
Memantine Hcl1,089$28,697
Rivastigmine148$27,683
Donepezil Hcl1,468$17,196
Memantine Hcl ErMemantine Hcl127$12,565
Sertraline Hcl476$4,783
RivastigmineRivastigmine Tartrate65$3,289
Escitalopram Oxalate106$1,852
Quetiapine Fumarate115$1,452
Mirtazapine66$1,267
Duloxetine Hcl13$613
Trazodone Hcl87$563
Risperidone15$136
Clonazepam11$64
Alprazolam13$9

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric$30$46,15328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →